title: The introduction of dengue vaccine may temporarily cause large spikes in prevalence.
abstract: A dengue vaccine is expected to be available within a few years. Once vaccine is available, policy-makers will need to develop suitable policies to allocate the vaccine. Mathematical models of dengue transmission predict complex temporal patterns in prevalence, driven by seasonal oscillations in mosquito abundance. In particular, vaccine introduction may induce a transient period immediately after vaccine introduction where prevalence can spike higher than in the pre-vaccination period. These spikes in prevalence could lead to doubts about the vaccination programme among the public and even among decision-makers, possibly impeding the vaccination programme. Using simple dengue transmission models, we found that large transient spikes in prevalence are robust phenomena that occur when vaccine coverage and vaccine efficacy are not either both very high or both very low. Despite the presence of transient spikes in prevalence, the models predict that vaccination does always reduce the total number of infections in the 15 years after vaccine introduction. We conclude that policy-makers should prepare for spikes in prevalence after vaccine introduction to mitigate the burden of these spikes and to accurately measure the effectiveness of the vaccine programme.
authors.affiliation: Department of Mathematical Sciences,Clemson University,Clemson, SC,USA.
authors.forename: A
authors.initials: A
authors.lastname: Pandey
authors.affiliation: Department of Biomedical Sciences,Oregon State University,Corvallis, OR,USA.
authors.forename: J
authors.initials: J
authors.lastname: Medlock
mesh_terms: D003715:Dengue / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D053059:Dengue Vaccines / Q000627:therapeutic use*; D003716:Dengue Virus; D006801:Humans; D017589:Immunization Programs / Q000379:methods; D015233:Models, Statistical; D015995:Prevalence
chemical_list: D053059:Dengue Vaccines
keywords: vaccination effectiveness
references.citation: Lancet. 2012 Nov 3;380(9853):1535-6
references.pmid: 22975339
references.citation: Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2238-43
references.pmid: 18250338
references.citation: Curr Opin Immunol. 2011 Jun;23(3):391-8
references.pmid: 21514129
references.citation: J Math Biol. 1999 Nov;39(5):439-69
references.pmid: 10602912
references.citation: Math Biosci. 2013 Dec;246(2):252-9
references.pmid: 24427785
references.citation: J Emerg Trauma Shock. 2011 Jan;4(1):120-7
references.pmid: 21633580
references.citation: Science. 1997 Jan 3;275(5296):65-7
references.pmid: 8974392
references.citation: Am J Trop Med Hyg. 2003 Feb;68(2):191-202
references.pmid: 12641411
references.citation: J R Soc Interface. 2013 Jul 03;10(86):20130414
references.pmid: 23825116
references.citation: Nat Rev Microbiol. 2010 Dec;8(12 Suppl):S7-16
references.pmid: 21079655
references.citation: Nature. 2001 Dec 13;414(6865):716-23
references.pmid: 11742391
references.citation: Clin Microbiol Rev. 1998 Jul;11(3):480-96
references.pmid: 9665979
references.citation: Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15259-64
references.pmid: 16217017
references.citation: Adv Virus Res. 2003;60:421-67
references.pmid: 14689700
references.citation: Lancet Infect Dis. 2002 Jan;2(1):33-42
references.pmid: 11892494
references.citation: PLoS Negl Trop Dis. 2012;6(3):e1450
references.pmid: 22479655
references.citation: Math Biosci. 2008 Feb;211(2):265-81
references.pmid: 17923138
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11802-7
references.pmid: 16868086